AstraZeneca withdraws its Covid-19 vaccine from sale for “commercial reasons”


A nurse holds vials of AstraZeneca vaccine against Covid-19, April 9, 2021. MANU FERNANDEZ / AP

The British pharmaceutical giant AstraZeneca announced on Wednesday May 8 that it was withdrawing from sale its Covid-19 vaccine Vaxzevria (the name of the AstraZeneca vaccine), one of the first to be put on the market during the pandemic. citing commercial reasons.

“As multiple vaccines against Covid-19 have been developed, there is a surplus of updated vaccines” faced with the different variants of the virus, “which resulted in a decline in demand”justified the group in a press release. “AstraZeneca has therefore taken the decision to initiate the withdrawal of the marketing authorization for Vaxzevria in Europe”according to the document received Wednesday by Agence France-Presse (AFP).

Read also | Article reserved for our subscribers In France, the AstraZeneca vaccine is now used exclusively to supply Covax

Add to your selections

The European Medicines Agency (EMA) wrote on its website on Tuesday that the authorization for the sale of Vaxzevria had been withdrawn “at the request of the marketing authorization holder”, namely the pharmaceutical laboratory. The group will also “work with other regulators around the world to initiate withdrawals of marketing authorizations for Vaxzevria where there is no expected future demand for the vaccine”.

In its press release, AstraZeneca says it wants “conclude this chapter”. A Source close to the group stressed to AFP that there was no “haven’t had any sales for a while”. “We are incredibly proud of the role Vaxzevria has played in ending the pandemic”adds the press release, which affirms that “according to independent estimates, more than 6.5 million lives were saved in the first year of use alone” serum, “and more than 3 billion doses have been distributed around the world”.

Vaccine having suffered several setbacks

If AstraZeneca’s profit jumped 21% year-on-year in the first quarter, driven particularly by oncology sales, the group has been reporting for months a constant decline in sales of drugs linked to Covid-19 – all like its rival GSK, which had been largely left behind in the race to develop a vaccine.

This vaccine, one of the very first on the market even though serums were not AstraZeneca’s specialty, had suffered several setbacks, including marketing authorization which never arrived in the United States. . It also experienced delivery problems in Europe, combined with suspicions of increased risks of thrombosis following several deaths.

AstraZeneca says it updated information on Vaxzevria in April 2021, with the agreement of the British regulator MHRA, to include the possibility that it could trigger thrombosis in rare cases. The United Kingdom, which first relied on Vaxzevria at the start of its anti-Covid vaccination campaign, then replaced it with competing serums.

The group regularly recalls that regulators and various states which have authorized the vaccine have estimated that “the benefits of vaccination far outweigh the risks of extremely rare side effects”.

The World with AFP

Reuse this content


PREV Indian Prime Minister Modi, seeking reform legacy, changes income targets for struggling farmers
NEXT How Google Maps keeps making mistakes on the road